RxDoctor Payments Data

Waymon Drummond, MD

Internal Medicine · Dallas, TXNPI 1659310597

Payments from drug & device makers

$1,471,094in general payments, 2019–2025

Across 214 payments — averaging $6874.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Taro Pharmaceuticals USA, Inc.$1.3M
  • Teva Pharmaceuticals USA, Inc.$91K
  • Novartis$25K
  • Pfizer$19K
  • Swedish Orphan Biovitrum AB$15K
  • Sanofi Pasteur Inc.$9K
  • plus $7K from 12 others

What the payments were for

  • Food & beverage$1,72090%
  • Education$19810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,471,094 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$26,483
Medicare patients
45
Services billed
168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide60$62,987
FarxigaDapagliflozin Propanediol25$35,307
EdarbyclorAzilsartan Med/Chlorthalidone40$14,382
RybelsusSemaglutide11$12,264
NamzaricMemantine Hcl/Donepezil Hcl12$11,054
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid23$2,587
Nebivolol Hcl54$2,499
PremarinEstrogens, Conjugated12$2,342
Tadalafil17$2,128
Rosuvastatin Calcium153$1,837
Telmisartan70$1,457
Celecoxib71$1,267
Colchicine14$1,232
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med29$942
Gabapentin46$885

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$179$75,25071 claims
AstraZenecaFarxiga$736$35,30725 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$414$14,38240 claims
PfizerPremarin$18,625$2,34212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →